Generic Portal
— Research Explorer
Full Professor, Deputy head Department of Hematology
Experimental Immunology
Clinical Haematology
AII - Cancer immunology
CCA - Cancer biology and immunology
Research interests
I am the leader of the theme ‘Tumor Immunology’ of the Cancer Center Amsterdam, a new research institute that combines the research programs of the 2 University Medical Centers in Amsterdam. After my PhD I set up a research group that performs both pre-clinical and translational studies with focus on (immune)biology and treatment of B-cell malignancies with CLL as main disease serving as a B-cell malignancy model. These studies were combined with both phase 1, 2 and 3 clinical trials for which he started an international network. These efforts have positioned the research group as the foremost clinical and translational CLL Center in the Netherlands and enabled me to build a large countrywide CLL biobank. As exemplified by a recent invited editorial in one of the leading medical journals in this field I am positioned as renowned international expert in this field (see ref. 2). See below a listed selection of achievements:
- Basic/translational research:
- Tumor microenvironment (TME): In vitro models simulating the tumor microenvironment of lymphnodes have been created within my group. This enabled pivotal studies which uncovered the important role of the TME in this disease which contributed to the development of novel targeted inhibitors. In vivo confirmation of this findings were established in an adapted CLL mouse model.
- Functional genetic studies: I have set up an European network to study the relevance of specific recurrent genetic aberrations in CLL, especially in relation to drug sensitivity. This work contributed to recognition of specific mutations such as TP53 that are now routinely tested to guide treatment decisions
- Adaptive immune responses: I have developed a track record of studies on the adaptive immune system in CLL. As T cells are a very small minority of total leukocytes in CLL (<5 to 1%), sophisticated methods have been set-up to facilitate such studies. These efforts made our group one of the main contributors to current knowledge on T cell dysfunction in CLL.
- Clinical research: When I took over the chairman position of the Dutch/Belgian HOVON CLL working group end of 2014, there were no open or planned trials. I reorganized the group, established an alliance with the Nordic CLL study group and (re)strengthened ties with other European study groups (especially the German CLL study group) and with pharma-industry. This has resulted in multiple international multicenter trials with novel agents in which my institute serves as central diagnostic and research laboratory for Netherlands and Belgium. Greatest achievement in this field has been the Hovon-associated global phase 3 MURANO study of which I am the principal investigator, which resulted in the establishment of a (practicing changing) new standard-of-care treatment for relapsed CLL patients.
Employment
Full Professor
Experimental Immunology
Academic Medical Center1 Jan 2014 → present
Full Professor
Clinical Haematology
Academic Medical Center1 Jan 2015 → present
Full Professor
AII - Cancer immunology
Academic Medical Center1 Jan 2016 → 31 Dec 9999
Full Professor
CCA - Cancer biology and immunology
Academic Medical Center1 Jan 2016 → 31 Dec 9999
President
Stichting Hovon Amsterdam, p/a VUmc1 Jan 2023 → …
Board member
European School of Hematology2021 → …
Board member
Wetenschappelijke raad Hematon2021 → …
Chairman
EHA Scientific Working group of CLL2020 → …
Chairman
HOVON CLL studygroup1 Oct 2018 → …
Consultant / Advisor
Janssen, Abbvie, Roche/Genentech, BMS, Astra Zeneca, LAVA, Biogeneration, LINK2018 → …
Board member
Eueropean Research Initiative of CLL2017 → …
Research outputs
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019
van der Straten, L., Levin, M-D., Dinnessen, M. A. W., Visser, O., Posthuma, E. F. M., Doorduijn, J. K., Langerak, A. W., Kater, A. P. & Dinmohamed, A. G., Dec 2023, In: Blood cancer journal. 13, 1, p. 15 1 p., 15.A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
Lameris, R., Ruben, J. M., Iglesias-Guimarais, V., de Jong, M., Veth, M., van de Bovenkamp, F. S., de Weerdt, I., Kater, A. P., Zweegman, S., Horbach, S., Riedl, T., Winograd, B., Roovers, R. C., Adang, A. E. P., de Gruijl, T. D., Parren, P. W. H. I. & van der Vliet, H. J., 21 Mar 2023, In: Cell Reports Medicine. 4, 3, p. 100961 100961.Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
Thus, Y. J., de Rooij, M. F. M., Swier, N., Beijersbergen, R. L., Guikema, J. E. J., Kersten, M-J., Eldering, E., Pals, S. T., Kater, A. P. & Spaargaren, M., 1 Mar 2023, In: Haematologica. 108, 3, p. 797-810 14 p.Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors
Martens, A. W. J., Kavazovi?, I., Krapi?, M., Pack, S. M., Arens, R., Jongejan, A., Moerland, P. D., Eldering, E., van der Windt, G. J. W., Wensveen, F. M., Peters, F. S. & Kater, A. P., Mar 2023, In: Leukemia. 37, 3, p. 606-616 11 p.Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: a randomized, controlled trial
Huygens, S., Hofsink, Q., Nijhof, I. S., Goorhuis, A., Kater, A. P., Te Boekhorst, P. A., Swaneveld, F., Novotný, V. M., Bogers, S., Welkers, M. R., Papageorgiou, G., Rijnders, B. J. & Heijmans, J., 11 Jan 2023, In: The Journal of infectious diseases. 227, 2, p. 206-210 5 p.Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
Kielbassa, K., Haselager, M. V., Bax, D. J. C., van Driel, B. F., Dubois, J., Levin, M-D., Kersting, S., Svanberg, R., Niemann, C. U., Kater, A. P. & Eldering, E., 2023, (E-pub ahead of print) In: Leukemia.Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
Antic, D., Milic, N., Chatzikonstantinou, T., Scarfò, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuéllar-García, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., & 81 others, Dec 2022, In: JOURNAL OF HEMATOLOGY & ONCOLOGY. 15, 1, p. 116 116.SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma
Leeksma, A. C., Derks, I. A. M., Garrick, B., Jongejan, A., Colombo, M., Bloedjes, T., Trowe, T., Leisten, J. C., Howarth, M., Malek, M., Mortensen, D. S., Blease, K., Groza, M. C., Narla, R. K., Loos, R., Kersten, M-J., Moerland, P. D., Guikema, J. E. J., Kater, A. P., Eldering, E., & 1 others, 18 Nov 2022, (E-pub ahead of print) In: Molecular oncology.Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19
COBRA KAI Study Team, Haggenburg, S., Hofsink, Q., Lissenberg-Witte, B. I., Broers, A. E. C., van Doesum, J. A., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., Burger, J. A., Bouhuijs, J. H., Smits, G. P., Wouters, D., van Leeuwen, E. M. M., Bontkes, H. J., Kootstra, N. A., Zweegman, S., Kater, A. P., Heemskerk, M. H. M., & 9 others, 1 Oct 2022, In: JAMA oncology. 8, 10, p. 1477-1483 7 p.CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study
Munir, T., Moreno, C., Owen, C., Follows, G., Benjamini, O., Janssens, A., Levin, M-D., Osterborg, A., Robak, T., Simkovic, M., Stevens, D., Voloshin, S., Vorobyev, V., Yagci, M., Ysebaert, L., Qi, Q., Steele, A., Schuier, N., Baeten, K., Caces, D. B., & 2 others, 1 Oct 2022, In: Clinical lymphoma, myeloma & leukemia. 22, p. S264-S265Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
Collins, M. A., Jung, I-Y., Zhao, Z., Apodaca, K., Kong, W., Lundh, S., Fraietta, J. A., Kater, A. P., Sun, C., Wiestner, A. & Melenhorst, J. J., Sept 2022, In: Cancer research communications. 2, 9, p. 1089-1103 15 p.Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
Thus, Y. J., Eldering, E., Kater, A. P. & Spaargaren, M., Sept 2022, In: Leukemia. 36, 9, p. 2165-2176 12 p.Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D'Rozario, J., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Panchal, A., Lu, T., Wu, J. Q., Jiang, Y., Lefebure, M., Boyer, M., & 1 others, 25 Aug 2022, In: Blood. 140, 8, p. 839-850 12 p.Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
Chen, Z., Simon-Molas, H., Cretenet, G., Valle-Argos, B., Smith, L. D., Forconi, F., Schomakers, B. V., van Weeghel, M., Bryant, D. J., van Bruggen, J. A. C., Peters, F. S., Rathmell, J. C., van der Windt, G. J. W., Kater, A. P., Packham, G. & Eldering, E., 11 Aug 2022, In: Blood. 140, 6, p. 630-643 14 p.Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Thompson, M. C., Harrup, R. A., Coombs, C. C., Roeker, L. E., Pu, J. J., Choi, M. Y., Barr, P. M., Allan, J. N., Simkovi, M., Leslie, L., Rhodes, J., Chong, E. A., Kamdar, M., Skarbnik, A., Lansigan, F., McCall, B., Saja, K., Dyer, M. J. S., Walter, H. S., Lefebure, M., & 18 others, 9 Aug 2022, In: Blood advances. 6, 15, p. 4553-4557 5 p.Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Davies, A., Kater, A. P., Sharman, J. P., Stilgenbauer, S., Vitolo, U., Klein, C., Parreira, J. & Salles, G., Aug 2022, In: Future oncology (London, England). 18, 26, p. 2943-2966 24 p.Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
van Bruggen, A. A. C., van der Windt, G. J. W., Hoogendoorn, M., Dubois, J., Kater, A. P. & Peters, F. S., 26 Jul 2022, In: Blood advances. 6, 14, p. 4185-4195 11 p., 14.Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110
Hengeveld, P. J., Ertem, Y. E., Dubois, J. M. N., Mellink, C. H. M., van der Kevie-Kersemaekers, A-M., Evers, L. M., Heezen, K., Kolijn, P. M., Mook, O. R. F., Motazacker, M. M., Nasserinejad, K., Kersting, S., Westerweel, P. E., Niemann, C. U., Kater, A. P., Langerak, A. W. & Levin, M-D., Jul 2022, In: Leukemia. 36, 7, p. 1935-1938 4 p.Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
Kater, A. P., Levin, M-D., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., van der Kevie-Kersemaekers, A-M. F., Dobber, J. A., Poulsen, C. B., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J., Brieghel, C., Mattsson, M., Bellido, M., Tran, H. T. T., & 2 others, 1 Jun 2022, In: The Lancet Oncology. 23, 6, p. 818-828 11 p.T-cell subset composition and functionality in patients with Waldenström's macroglobulinemia
Amaador, K., Martens, A., de Boer, R., Rietveld, J., Heemskerk, M., Rutten, C. E., Eldering, E., Kersten, M-J., Kater, A. P., Vos, J. & Tonino, S., Jun 2022, In: Leukemia & lymphoma. 63, 6, p. 1469-1473 5 p.A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
Sharman, J. P., Biondo, J. M. L., Boyer, M., Fischer, K., Hallek, M., Jiang, D., Kater, A. P., Porro Lurà, M. & Wierda, W. G., May 2022, In: EJHaem. 3, 2, p. 492-506 15 p.Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
Martens, A. W. J., Rietveld, J. M., de Boer, R., Peters, F. S., Ngo, A., van Mil, L. W. H. G., de Heer, K., Spaargaren, M., Verkleij, C. P. M., van de Donk, N. W. C. J., Adams, H. C., Eldering, E., van Noesel, C. J. M., Verona, R. & Kater, A. P., May 2022, In: Cancer research communications. 2, 5, p. 330-341 12 p.Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
Baliakas, P., Espinet, B., Mellink, C., Jarosova, M., Athanasiadou, A., Ghia, P., Kater, A. P., Oscier, D., Haferlach, C. & Stamatopoulos, K., 25 Apr 2022, In: HemaSphere. 6, 4, p. E707Sodium stibogluconate and CD47-SIRPa blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
van Rees, D. J., Brinkhaus, M., Klein, B., Verkuijlen, P., Tool, A. T. J., Schornagel, K., Treffers, L. W., van Houdt, M., Kater, A. P., Vidarsson, G., Gennery, A. R., Kuijpers, T. W., van Bruggen, R., Matlung, H. L. & van den Berg, T. K., 12 Apr 2022, In: Blood advances. 6, 7, p. 2156-2166 11 p.Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018
van der Straten, L., Maas, C. C. H. M., Levin, M-D., Visser, O., Posthuma, E. F. M., Doorduijn, J. K., Langerak, A. W., Kater, A. P. & Dinmohamed, A. G., 1 Apr 2022, In: Blood cancer journal. 12, 4, 72.Do CARs finally hit the CLL road?
Kater, A. P. & Melenhorst, J. J., 24 Mar 2022, In: Blood. 139, 12, p. 1775-1776 2 p.Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
Haggenburg, S., Lissenberg-Witte, B. I., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., de Rooij, D. M., van Meerloo, J., Cloos, J., Kootstra, N. A., Wouters, D., Weijers, S. S., van Leeuwen, E. M. M., Bontkes, H. J., Tonouh-Aajoud, S., Heemskerk, M. H. M., Sanders, R. W., Roelandse-Koop, E., Hofsink, Q., Groen, K., & 28 others, 8 Mar 2022, In: Blood advances. 6, 5, p. 1537-1546 10 p.Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
HOVON CLL study group, Mar 2022, In: The Lancet Haematology. 9, 3, p. e190-e199Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O'Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., Pagel, J. M., & 8 others, 15 Feb 2022, In: Clinical cancer research. 28, 4, p. 603-608 6 p.Conditional relative survival among patients with chronic lymphocytic leukaemia: A population-based study in the Netherlands
van der Straten, L., Levin, M-D., Visser, O., Posthuma, E. F. M., Doorduijn, J. K., Kater, A. P. & Dinmohamed, A. G., Feb 2022, In: EJHaem. 3, 1, p. 180-183 4 p.Increasing CART cell engine performance in CLL
Peters, F. S. & Kater, A. P., 27 Jan 2022, In: Blood. 139, 4, p. 473-474 2 p.Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group
HOVON CLL study group, 2022, In: Leukemia & lymphoma. 63, 10, p. 2276-2289 14 p.JAK–STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL
Haselager, M. V., Thijssen, R., Bax, D., Both, D., de Boer, F., Mackay, S., Dubois, J., Mellink, C., Kater, A. P. & Eldering, E., 2022, (E-pub ahead of print) In: Molecular oncology.Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
Haggenburg, S., Hofsink, Q., Lissenberg-Witte, B. I., Broers, A. E. C., van Doesum, J. A., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., Burger, J. A., Bouhuijs, J. H., Smits, G. P., Wouters, D., van Leeuwen, E. M. M., Bontkes, H. J., Kootstra, N. A., Zweegman, S., Kater, A. P., Heemskerk, M. H. M., Groen, K., & 9 others, 2022.Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
Kater, A. P., Slinger, E., Cretenet, G., Martens, A. W., Balasubramanian, S., Leverson, J. D. & Eldering, E., 14 Dec 2021, In: Blood advances. 5, 23, p. 5410-5414 5 p.Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
van der Straten, L., Hengeveld, P. J., Kater, A. P., Langerak, A. W. & Levin, M-D., 9 Dec 2021, In: Frontiers in oncology. 11, 780085.COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Chatzikonstantinou, T., Kapetanakis, A., Scarfò, L., Karakatsoulis, G., Allsup, D., Cabrero, A. A., Andres, M., Antic, D., Baile, M. N., Baliakas, P., Bron, D., Capasso, A., Chatzileontiadou, S., Cordoba, R., Correa, J-G., Cuéllar-García, C., de Paoli, L., de Paolis, M. R., del Poeta, G., Demosthenous, C., & 93 others, Dec 2021, In: Leukemia. 35, 12, p. 3444-3454 11 p.Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., Garcia-Marco, J. A., Mato, A., Pinilla-Ibarz, J., Seymour, J. F., Lepretre, S., Stilgenbauer, S., Robak, T., Rothbaum, W., Izumi, R., Hamdy, A., & 4 others, 1 Nov 2021, In: Journal of clinical oncology. 39, 31, p. 3441-3452 12 p.Correction: Van bruggen et al. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma (Cancers (2020), 12, (3837), 10.3390/cancers12123837)
van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H. & Kater, A. P., 1 Oct 2021, In: Cancers. 13, 19, 4738.Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Al-Sawaf, O., Seymour, J. F., Kater, A. P. & Fischer, K., Aug 2021, In: Hematology/oncology clinics of North America. 35, 4, p. 775-791 17 p.Co-stimulatory versus cell death aspects of agonistic cd40 monoclonal antibody selicrelumab in chronic lymphocytic leukemia
Delgado, R., Kielbassa, K., ter Burg, J., Klein, C., Trumpfheller, C., de Heer, K., Kater, A. P. & Eldering, E., 2 Jun 2021, In: Cancers. 13, 12, 3084.T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
Peters, F. S., Strefford, J. C., Eldering, E. & Kater, A. P., 1 May 2021, In: Haematologica. 106, 5, p. 1234-1243 10 p.Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
Haselager, M., Thijssen, R., West, C., Young, L., van Kampen, R., Willmore, E., Mackay, S., Kater, A. & Eldering, E., May 2021, In: Cell death and differentiation. 28, 5, p. 1658-1668 11 p.Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
ERIC, the European Research Initiative on CLL, 11 Mar 2021, In: Blood. 137, 10, p. 1365-1376 12 p.A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia
de Weerdt, I., Lameris, R., Ruben, J. M., de Boer, R., Kloosterman, J., King, L. A., Levin, M-D., Parren, P. W. H. I., de Gruijl, T. D., Kater, A. P. & van der Vliet, H. J., 1 Mar 2021, In: Clinical cancer research. 27, 6, p. 1744-1755 12 p.Human CXCR5+PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies
Hofland, T., Martens, A. W. J., van Bruggen, J. A. C., de Boer, R., Schetters, S., Remmerswaal, E. B. M., Bemelman, F. J., Levin, M-D., Bins, A. D., Eldering, E., Kater, A. P. & Tonino, S. H., Mar 2021, In: European journal of immunology. 51, 3, p. 703-713 11 p.Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
Niemann, C. U., Levin, M-D., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., Dobber, J. A., Poulsen, C. B., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J., Mattsson, M., Bellido, M., Tran, H. T. T., Nasserinejad, K. & Kater, A. P., 25 Feb 2021, In: Blood. 137, 8, p. 1117-1120 4 p.Kinase inhibitors developed for treatment of hematologic malignancies: Implications for immune modulation in COVID-19
Jacobs, C. F., Eldering, E. & Kater, A. P., 9 Feb 2021, In: Blood advances. 5, 3, p. 913-924 12 p.The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer
Leeksma, A. C., Derks, I. A. M., Kasem, M. H., Kilic, E., de Klein, A., Jager, M. J., van de Loosdrecht, A. A., Jansen, J. H., Navrkalova, V., Faber, L. M., Zaborsky, N., Egle, A., Zenz, T., Pospisilova, S., Abdel-Wahab, O., Kater, A. P. & Eldering, E., 29 Jan 2021, In: Frontiers in oncology. 10, 609409.A bispecific antibody antagonizes prosurvival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies
de Weerdt, I., Lameris, R., Scheffer, G. L., Vree, J., de Boer, R., Stam, A. G., van de Ven, R., Levin, M-D., Pals, S. T., Roovers, R. C., Parren, P. W. H. I., de Gruijl, T. D., Kater, A. P. & van der Vliet, H. J., 1 Jan 2021, In: Cancer immunology research. 9, 1, p. 50-61 12 p.Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: A multi-center study
ERIC, the European Research Initiative on CLL, Leeksma, A. C., Baliakas, P., Moysiadis, T., Puiggros, A., Plevova, K., van der Kevie-Kersemaekers, A-M., Posthuma, H., Rodriguez-Vicente, A. E., Tran, A. N., Barbany, G., Mansouri, L., Gunnarsson, R., Parker, H., van den Berg, E., Bellido, M., Davis, Z., Wall, M., Scarpelli, I., Österborg, A., & 19 others, 1 Jan 2021, In: Haematologica. 105, 5Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., Hallek, M., ESMO Guidelines Committee & Mey, U., Jan 2021, In: Annals of oncology. 32, 1, p. 23-33 11 p.A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors
Janssen, J., Donner, N., Li, Z., Wormhoudt, T. A. M., Wagner, K., Guikema, J. E. J., van der Schoot, C. E., Kater, A. P., Feizi, T., Bende, R. J. & van Noesel, C. J. M., 2021, (E-pub ahead of print) In: HemaSphere. e550.B-cell receptor stereotyped subsets and outcome for patients with chronic lymphocytic leukemia in the HOVON 68 trial
HOVON 68 trial group, 2021, In: Journal of Translational Genetics and Genomics. 5, 2, p. 182-188The effect of a Clinical Decision Support System on the frequency of dose adjustments of anticancer drugs in case of renal or hepatic dysfunction
Rolvink, J., Gerards, A-L. E., Kater, A. P., Swart, E. L. & Becker, M. L., 2021, (E-pub ahead of print) In: Journal of oncology pharmacy practice.Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
Haselager, M. V., Kielbassa, K., ter Burg, J., Bax, D. J. C., Fernandes, S. M., Borst, J., Tam, C., Forconi, F., Chiodin, G., Brown, J. R., Dubois, J., Kater, A. P. & Eldering, E., 17 Dec 2020, In: Blood. 136, 25, p. 2918-2926 9 p.Overcoming the hurdles of autologous t‐cell‐based therapies in b‐cell non‐hodgkin lymphoma
van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H. & Kater, A. P., 1 Dec 2020, In: Cancers. 12, 12, p. 1-31 31 p., 3837.Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Kater, A. P., Wu, J. Q., Kipps, T., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., Owen, C., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Dubois, J., Eldering, E., Mellink, C., van der Kevie-Kersemaekers, A-M., Kim, S. Y., Chyla, B., Punnoose, E., & 8 others, 1 Dec 2020, In: Journal of clinical oncology. 38, 34, p. 4042-4054 13 p.Protocol description of the HOVON 141/VISION trial: A prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
Levin, M-D., Kater, A., Mattsson, M., Kersting, S., Ranti, J., Thi Tuyet Tran, H., Nasserinejad, K. & Niemann, C. U., 15 Oct 2020, In: BMJ open. 10, 10, 039168.Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
Haselager, M. V., Kater, A. P. & Eldering, E., 8 Oct 2020, In: Frontiers in oncology. 10, 592205.COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Scarfò, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernández-Rivas, J. Á., Mirás, F., Baile, M. N., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., & 62 others, 1 Sept 2020, In: Leukemia. 34, 9, p. 2354-2363 10 p.Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
Saberi Hosnijeh, F., van der Straten, L., Kater, A. P., van Oers, M. H. J., Posthuma, W. F. M., Chamuleau, M. E. D., Bellido, M., Doorduijn, J. K., van Gelder, M., Hoogendoorn, M., de Boer, F., te Raa, G. D., Kerst, J. M., Marijt, E. W. A., Raymakers, R. A. P., Koene, H. R., Schaafsma, M. R., Dobber, J. A., Tonino, S. H., Kersting, S. S., & 2 others, Sept 2020, In: Experimental hematology. 89, p. 55-60.e6COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Fürstenau, M., Langerbeins, P., de Silva, N., Fink, A. M., Robrecht, S., von Tresckow, J., Simon, F., Hohloch, K., Droogendijk, J., van der Klift, M., van der Spek, E., Illmer, T., Schöttker, B., Fischer, K., Wendtner, C. M., Tausch, E., Stilgenbauer, S., Niemann, C. U., Gregor, M., Kater, A. P., & 2 others, 1 Aug 2020, In: Leukemia. 34, 8, p. 2225-2229 5 p.Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine
Kuipers, M. T., van Zwieten, R., Heijmans, J., Rutten, C. E., de Heer, K., Kater, A. P. & Nur, E., 1 Aug 2020, In: American journal of hematology. 95, 8, p. E194-E196Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab
Kater, A. P., Jiang, Y., Chyla, B. & Seymour, J. F., 1 Jul 2020, In: Haematologica. 105, 7, p. e382-e383CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Martens, A. W. J., Janssen, S. R., Derks, I. A. M., Adams Iii, H. C., Izhak, L., van Kampen, R., Tonino, S. H., Eldering, E., van der Windt, G. J. W. & Kater, A. P., 1 Jun 2020, In: Journal for immunotherapy of cancer. 8, 1CAR-T and ibrutinib vs CLL: Sequential or simultaneous?
Kater, A. P. & Joseph Melenhorst, J., 7 May 2020, In: Blood. 135, 19, p. 1611-1612 2 p.Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia
van der Straten, L., Kater, A. P., Doorduijn, J. K., van den Broek, E. C., Posthuma, E. F. M., Dinmohamed, A. G. & Levin, M-D., 1 May 2020, In: Annals of hematology. 99, 5, p. 1081-1091 11 p.Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016
van der Straten, L., Levin, M-D., Visser, O., Posthuma, E. F. M., Doorduijn, J. K., Kater, A. P. & Dinmohamed, A. G., 1 May 2020, In: British journal of haematology. 189, 3, p. 574-577 4 p.The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands
van der Straten, L., Levin, M-D., Visser, O., Blijlevens, N. M. A., Cornelissen, J. J., Doorduijn, J. K., Kater, A. P. & Dinmohamed, A. G., 1 Mar 2020, In: British journal of haematology. 188, 6, p. e109-e112Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
Deng, R., Gibiansky, L., Lu, T., Li, X., Lu, D., Li, C., Girish, S., Wang, J., Boyer, M., Shankar, N., Humphrey, K., Freise, K. J., Salem, A. H., Seymour, J. F., Kater, A. P. & Miles, D., 2 Jan 2020, In: Leukemia & lymphoma. 61, 1, p. 56-65 10 p.Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib
Svanberg, R., Ostrowski, S. R., Nasserinejad, K., Kersting, S., Dobber, J. A., Mattson, M., Tran, H. T. T., Levin, M-D., Mous, R., Kater, A. P. & Niemann, C. U., 2020, In: Leukemia & lymphoma. 61, 14, p. 3422-3431 10 p.Functional Differences between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
Hofland, T., de Weerdt, I., Endstra, S., Jongejan, A., Platenkamp, L., Remmerswaal, E. B. M., Moerland, P. D., ten Berge, I. J. M., Levin, M-D., Kater, A. P. & Tonino, S. H., 2020, In: HemaSphere. 4, 2Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented in Vitro by Adequate Activating Signaling
Hofland, T., Endstra, S., Gomes, C. K. P., de Boer, R., de Weerdt, I., Bobkov, V., Riedl, J. A., Heukers, R., Smit, M. J., Eldering, E., Levin, M-D., Kater, A. P. & Tonino, S. H., 1 Dec 2019, In: HemaSphere. 3, 6, e308.Rare but Serious: Ibrutinib Induced Liver Failure
Kleijwegt, F. S., Roda, A. A., Rolvink, J., Kater, A. P., Kersten, M. J. & Vos, J. M. I., 1 Dec 2019, In: HemaSphere. 3, 6, p. e307Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study
Deng, R., Gibiansky, L., Lu, T., Agarwal, P., Ding, H., Li, X., Kshirsagar, S., Lu, D., Li, C., Girish, S., Wang, J., Boyer, M., Humphrey, K., Freise, K. J., Salem, A. H., Seymour, J. F., Kater, A. P. & Miles, D., Dec 2019, In: Clinical pharmacokinetics. 58, 12, p. 1621-1634Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study
Ruchlemer, R., Ben-Ami, R., Bar-Meir, M., Brown, J. R., Malphettes, M., Mous, R., Tonino, S. H., Soussain, C., Barzic, N., Messina, J. A., Jain, P., Cohen, R., Hill, B., Mulligan, S. P., Nijland, M., Herishanu, Y., Benjamini, O., Tadmor, T., Okamoto, K., Arthurs, B., & 9 others, Dec 2019, In: Mycoses. 62, 12, p. 1140-1147Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J. K., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., le Gouill, S., Oberic, L., Robak, T., & 7 others, Nov 2019, In: Leukemia. 33, 11, p. 2762-2766Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
de Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., van der Klift, M., Remmerswaal, E. B. M., Bemelman, F. J., Niemann, C. U., Kersting, S., Levin, M-D., Eldering, E., Tonino, S. H. & Kater, A. P., 10 Sept 2019, In: Blood advances. 3, 17, p. 2642-2652 11 p.Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
de Weerdt, I. & Kater, A. P., 1 Jun 2019, In: HemaSphere. 3, S2, p. 44-46Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Kater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., Verdugo, M., Wu, J., Punnoose, E. A., Jiang, Y., Wang, J., Boyer, M., Humphrey, K., Mobasher, M. & Kipps, T. J., 1 Feb 2019, In: Journal of clinical oncology. 37, 4, p. 269-277 9 p.Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
Leeksma, A. C., Taylor, J., Wu, B., Gardner, J. R., He, J., Nahas, M., Gonen, M., Alemayehu, W. G., te Raa, D., Walther, T., Hüllein, J., Dietrich, S., Claus, R., de Boer, F., de Heer, K., Dubois, J., Dampmann, M., Dürig, J., van Oers, M. H. J., Geisler, C. H., & 11 others, Feb 2019, In: Leukemia. 33, 2, p. 390-402 13 p.Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
JULIET Investigators, Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., & 18 others, 3 Jan 2019, In: New England journal of medicine. 380, 1, p. 45-56 12 p.Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
ERIC, the European Research Initiative on CLL, Baliakas, P., Jeromin, S., Iskas, M., Puiggros, A., Plevova, K., Nguyen-Khac, F., Davis, Z., Rigolin, G. M., Visentin, A., Xochelli, A., Delgado, J., Baran-Marszak, F., Stalika, E., Abrisqueta, P., Durechova, K., Papaioannou, G., Eclache, V., Dimou, M., Iliakis, T., & 23 others, 1 Jan 2019, In: Blood. 133, 11, p. 1205-1216 12 p.Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
HOVON CLL study group, Kater, A. P., van Oers, M. H. J., van Norden, Y., van der Straten, L., Driessen, J., Posthuma, W. F. M., Schipperus, M., Chamuleau, M. E. D., Nijland, M., Doorduijn, J. K., van Gelder, M., Hoogendoorn, M., de Croon, F., Wittebol, S., Kerst, J. M., Marijt, E. W. A., Raymakers, R. A. P., Schaafsma, M. R., Dobber, J. A., & 2 others, Jan 2019, In: Haematologica. 104, 1, p. 147-154 8 p.Ibrutinib: searching for a partner drug
Kater, A. P. & Brown, J. R., Jan 2019, In: lancet oncology. 20, 1, p. 3-5 3 p.Auto-immuuncytopenieën bij patiënten met chronische lymfatische leukemie: een beknopt overzicht met aanbevelingen voor de praktijk
de Back, T., Kater, A. & Tonino, S. H., 2019, In: Nederlands tijdschrift voor hematologie. 11, p. 321-328Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
van Bruggen, J. A. C., Martens, A. W. J., Fraietta, J. A., Hofland, T., Tonino, S. H., Eldering, E., Levin, M-D., Siska, P. J., Endstra, S., Rathmell, J. C., June, C. H., Porter, D. L., Melenhorst, J. J., Kater, A. P. & van der Windt, G. J. W., 2019, In: Blood. 134, 1, p. 44-58Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes
Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P. & Eldering, E., 2019, In: Journal of immunology (Baltimore, Md.. 203, 8, p. 2100-2109Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
Hofland, T., Eldering, E., Kater, A. P. & Tonino, S. H., 2019, In: International journal of molecular sciences. 20, 17Ibrutinib and venetoclax for first-line treatment of CLL
Kater, A. P., Levin, M-D. & Niemann, C. U., 2019, In: New England journal of medicine. 381, 8, p. 788-789Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy
van der Straten, L., Dinmohamed, A. G., Westerweel, P. E., Langerak, A. W., Riedl, J., Doorduijn, J. K., Kater, A. P. & Levin, M-D., Nov 2018, In: Leukemia & lymphoma. 59, 11, p. 2757-2761Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., Panizo, C., Shah, B., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., Le Gouill, S., Oberic, L., Robak, T., & 9 others, 2018, In: Lancet. 391, 10121, p. 659-667Authors reply: Venetoclax-Rituximab in Chronic Lymphocytic Leukemia
Seymour, J. F., Mobasher, M. & Kater, A. P., 2018, In: New England journal of medicine. 378, 22, p. 2143-2144 2 p.Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations
de Back, T. R., Kater, A. P. & Tonino, S. H., 2018, In: Expert review of hematology. 11, 8, p. 613-624Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands
Kersting, S., Neppelenbroek, S. I. M., Visser, H. P. J., van Gelder, M., Levin, M-D., Mous, R., Posthuma, W., van der Straaten, H. M. & Kater, A. P., 2018, In: Clinical lymphoma, myeloma & leukemia. 18, 1, p. 52-57ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., Gonzalez Diaz, M., Moreno, C., Gaidano, G., Stamatopoulos, K., Rosenquist, R., Stilgenbauer, S., Ghia, P. & Pospisilova, S., 2018, In: Leukemia. 32, p. 1070-1080Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
Kater, A. P., Tonino, S. H., Spiering, M., Chamuleau, M. E. D., Liu, R., Adewoye, A. H., Gao, J., Dreiling, L., Xin, Y., Doorduijn, J. K. & Kersten, M. J., 2018, In: Blood cancer journal. 8, 2, p. 16Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib
de Weerdt, I., Hofland, T., Lameris, R., Endstra, S., Jongejan, A., Moerland, P. D., de Bruin, R. C. G., Remmerswaal, E. B. M., ten Berge, I. J. M., Liu, N., van der Stelt, M., Faber, L. M., Levin, M-D., Eldering, E., Tonino, S. H., de Gruijl, T. D., van der Vliet, H. J. & Kater, A. P., 2018, In: Blood. 132, 21, p. 2260-2272Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
HOVON CLL study group., Kater, A. P., Kersting, S., van Norden, Y., Dubois, J., Dobber, J. A., Mellink, C. H., Evers, L. M., Croon-de Boer, F., Schreurs, J., van der Spek, E., Visser, H., Idink, C., Wittebol, S., Hoogendoorn, M., Tonino, S. H., Mobasher, M. & Levin, M-D., 2018, In: Blood advances. 2, 24, p. 3566-3571Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands
Dinmohamed, A. G., Posthuma, E. F. M., Visser, O., Kater, A. P., Raymakers, R. A. P. & Doorduijn, J. K., 2018, In: Blood. 131, p. 1380-1383Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Humerickhouse, R., Punnoose, E. A., Li, Y., Boyer, M., Humphrey, K., Mobasher, M. & Kater, A. P., 2018, In: New England journal of medicine. 378, 12, p. 1107-1120Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
Brown, J. R., Hamadani, M., Hayslip, J., Janssens, A., Wagner-Johnston, N., Ottmann, O., Arnason, J., Tilly, H., Millenson, M., Offner, F., Gabrail, N. Y., Ganguly, S., Ailawadh, S., Kasar, S., Kater, A. P., Doorduijn, J. K., Gao, L., Lager, J. J., Wu, B., Egile, C., & 1 others, 2018, In: Lancet. Haematology. 5, 4, p. e170-e180CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis
van Attekum, M. H. A., van Bruggen, J. A. C., Slinger, E., Lebre, M. C., Reinen, E., Kersting, S., Eldering, E. & Kater, A. P., 2017, In: Haematologica. 102, 12, p. 2069-2076Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling
Singh, S. P., Pillai, S. Y., de Bruijn, M. J. W., Stadhouders, R., Corneth, O. B. J., van den Ham, H. J., Muggen, A., van Ijcken, W., Slinger, E., Kuil, A., Spaargaren, M., Kater, A. P., Langerak, A. W. & Hendriks, R. W., 2017, In: Oncotarget. 8, 42, p. 71981-71995 15 p.Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
van Attekum, M. H. A., Eldering, E. & Kater, A. P., 2017, In: Haematologica. 102, 9, p. 1469-1476Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
de Weerdt, I., Koopmans, S. M., Kater, A. P. & van Gelder, M., 2017, In: Haematologica. 102, 10, p. 1629-1639Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
Fink, A. M., Bahlo, J., Robrecht, S., Al-Sawaf, O., Aldaoud, A., Hebart, H., Jentsch-Ullrich, K., Dörfel, S., Fischer, K., Wendtner, C-M., Nösslinger, T., Ghia, P., Bosch, F., Kater, A. P., Döhner, H., Kneba, M., Kreuzer, K-A., Tausch, E., Stilgenbauer, S., Ritgen, M., & 3 others, 2017, In: Lancet. Haematology. 4, 10, p. E475-E486Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia
van Attekum, M. H. A., Terpstra, S., Slinger, E., von Lindern, M., Moerland, P. D., Jongejan, A., Kater, A. P. & Eldering, E., 2017, In: Oncogene. 36, 26, p. 3651-3660Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection
van der Valk, M., Zaaijer, H. L., Kater, A. P. & Schinkel, J., 2017, In: Journal of hepatology. 66, 1, p. 242-243Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition
Slinger, E., Thijssen, R., Kater, A. P. & Eldering, E., 2017, In: Leukemia. 31, 12, p. 2601-2607T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy
Heijink, D. M., Kater, A. P., Hazenberg, M. D., Hagenbeek, A. & Kersten, M. J., May 2016, In: Netherlands journal of medicine. 74, 4, p. 147-51 5 p.A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., Palacio, C., Stehlikova, O., Kreuzer, K-A., Liptrot, S., O'Brien, D., de Tute, R. M., Marinov, I., Hauwel, M., Spacek, M., Dobber, J., Kater, A. P., Gambell, P., Soosapilla, A., Lozanski, G., & 31 others, 2016, In: Leukemia. 30, 4, p. 929-936Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA
Slinger, E., Wensveen, F. M., Guikema, J. E., Kater, A. P. & Eldering, E., 2016, In: Haematologica. 101, 9, p. e374-e377Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Thijssen, R., ter Burg, J., Garrick, B., van Bochove, G. G. W., Brown, J. R., Fernandes, S. M., Rodríguez, M. S., Michot, J-M., Hallek, M., Eichhorst, B., Reinhardt, H. C., Bendell, J., Derks, I. A. M., van Kampen, R. J. W., Hege, K., Kersten, M. J., Trowe, T., Filvaroff, E. H., Eldering, E. & Kater, A. P., 2016, In: Blood. 128, 4, p. 574-583Dutch guidelines for the diagnosis and treatment of chronic lymphocytic leukaemia
AUTHOR GROUP, 2016, In: Netherlands journal of medicine. 74, 2, p. 68-74Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study
van Gelder, M., van Oers, M. H., Alemayehu, W. G., Abrahamse-Testroote, M. C. J., Cornelissen, J. J., Chamuleau, M. E., Zachée, P., Hoogendoorn, M., Nijland, M., Petersen, E. J., Beeker, A., Timmers, G-J., Verdonck, L., Westerman, M., de Weerdt, O. & Kater, A. P., 2016, In: Bone marrow transplantation. 51, 6, p. 799-806Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia
de Weerdt, I., van Hoeven, V., Munneke, J. M., Endstra, S., Hofland, T., Hazenberg, M. D. & Kater, A. P., 2016, In: Haematologica. 101, 11, p. e461-e464Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling
van Attekum, M. H. A., Terpstra, S., Reinen, E., Kater, A. P. & Eldering, E., 2016, In: Cell death discovery. 2, p. 16020Richtlijn 'Chronische Lymfatische Leukemie'
Kersting, S., van Gelder, M., Levin, M. D., Mous, R., Posthuma, E. F. M., van der Straaten, H. M. & Kater, A. P., 2016, In: Nederlands tijdschrift voor hematologie. 2016, 13, p. 307-321Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia
Siska, P. J., van der Windt, G. J. W., Kishton, R. J., Cohen, S., Eisner, W., MacIver, N. J., Kater, A. P., Weinberg, J. B. & Rathmell, J. C., 2016, In: Journal of immunology (Baltimore, Md.. 197, 6, p. 2532-2540T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy
Heijink, D. M., Kater, A. P., Hazenberg, M. D., Hagenbeek, A. & Kersten, M. J., 2016, In: Netherlands journal of medicine. 74, 4, p. 147-151The APRIL paradox in normal versus malignant B cell biology
van Attekum, M. H. A., Kater, A. P. & Eldering, E., 2016, In: Cell death & disease. 7, 6, p. e2276The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
Thijssen, R., ter Burg, J., van Bochove, G. G. W., de Rooij, M. F. M., Kuil, A., Jansen, M. H., Kuijpers, T. W., Baars, J. W., Virone-Oddos, A., Spaargaren, M., Egile, C., van Oers, M. H. J., Eldering, E., Kersten, M. J. & Kater, A. P., 2016, In: Leukemia. 30, 2, p. 337-345The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 ( voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells (Vol 30, pg 337, 2016)
Thijssen, R., ter Burg, J., van Bochove, G. G. W., de Rooij, M. F. M., Kuil, A., Jansen, M. H., Kuijpers, T. W., Baars, J. W., Virone-Oddos, A., Spaargaren, M., Egile, C., van Oers, M. H. J., Eldering, E., Kersten, M. J. & Kater, A. P., 2016, In: Leukemia. 30, 9, p. 1963TP53 dysfunction in CLL: Implications for prognosis and treatment
te Raa, G. D. & Kater, A. P., 2016, In: Best practice & research. Clinical haematology. 29, 1, p. 90-99'Trained immunity': consequences for lymphoid malignancies
Stevens, W. B. C., Netea, M. G., Kater, A. P. & van der Velden, W. J. F. M., 2016, In: Haematologica. 101, 12, p. 1460-1468Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification
te Raa, G. D., Moerland, P. D., Leeksma, A. C., Derks, I. A., Yigittop, H., Laddach, N., Loden-van Straaten, M., Navrkalova, V., Trbusek, M., Luijks, D. M., Zenz, T., Skowronska, A., Hoogendoorn, M., Stankovic, T., van Oers, M. H., Eldering, E. & Kater, A. P., 2015, In: Cell death & disease. 6, p. e1852BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future
Spaargaren, M., de Rooij, M. F. M., Kater, A. P. & Eldering, E., 2015, In: Oncogene. 34, 19, p. 2426-2436Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
de Rooij, M. F. M., Kuil, A., Kater, A. P., Kersten, M. J., Pals, S. T. & Spaargaren, M., 2015, In: Blood. 125, 14, p. 2306-2309Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia
Tonino, S. H., Mulkens, C. E., van Laar, J., Derks, I. A. M., Suo, G., Croon-de Boer, F., van Oers, M. H. J., Eldering, E., Wang, J. Y. & Kater, A. P., 2015, In: Leukemia & lymphoma. 56, 8, p. 2439-2447p53-dependent non-coding RNA networks in chronic lymphocytic leukemia
Blume, C. J., Hotz-Wagenblatt, A., Hüllein, J., Sellner, L., Jethwa, A., Stolz, T., Slabicki, M., Lee, K., Sharathchandra, A., Benner, A., Dietrich, S., Oakes, C. C., Dreger, P., te Raa, D., Kater, A. P., Jauch, A., Merkel, O., Oren, M., Hielscher, T. & Zenz, T., 2015, In: Leukemia. 29, 10, p. 2015-2023PD-L1 blockade: rejuvenating T cells in CLL
Kater, A. P. & van der Windt, G. J. W., 2015, In: Blood. 126, 2, p. 126-128Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
Thijssen, R., Slinger, E., Weller, K., Geest, C. R., Beaumont, T., van Oers, M. H. J., Kater, A. P. & Eldering, E., 2015, In: Haematologica. 100, 8, p. e302-e306The 8th Young Investigators' Meeting on Chronic Lymphocytic Leukemia
Kater, A. P., Lanasa, M. C., Wesselmann, J. & Fischer, K., 2015, In: Leukemia & lymphoma. 56, 5, p. 1556-1559The impact of SF3B1 mutations in CLL on the DNA-damage response
te Raa, G. D., Derks, I. A. M., Navrkalova, V., Skowronska, A., Moerland, P. D., van Laar, J., Oldreive, C., Monsuur, H., Trbusek, M., Malcikova, J., Lodén, M., Geisler, C. H., Hüllein, J., Jethwa, A., Zenz, T., Pospisilova, S., Stankovic, T., van Oers, M. H. J., Kater, A. P. & Eldering, E., 2015, In: Leukemia. 29, 5, p. 1133-1142Acute sinusitis and blindness as the first presentation of chronic lymphocytic leukaemia
Lim, K. H., Thomas, G., van Beers, E. J., Hosman, A. E., Mourits, M. P., van Noesel, C. J. M., Kater, A. P. & Reinartz, S. M., 2014, In: Netherlands journal of medicine. 72, 10, p. 548-550Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach
te Raa, G. D., Malčiková, J., Mraz, M., Trbusek, M., Le Garff-Tavernier, M., Merle-Béral, H., Greil, R., Merkel, O., Pospíšilová, S., Lin, K., Pettitt, A. R., Stankovic, T., van Oers, M. H., Eldering, E., Stilgenbauer, S., Zenz, T. & Kater, A. P., 2014, In: British journal of haematology. 167, 4, p. 565-569CMV-specific CD8(+) T-cell function is not impaired in chronic lymphocytic leukemia
te Raa, G. D., Pascutti, M. F., García-Vallejo, J. J., Reinen, E., Remmerswaal, E. B. M., ten Berge, I. J. M., van Lier, R. A. W., Eldering, E., van Oers, M. H. J., Tonino, S. H. & Kater, A. P., 2014, In: Blood. 123, 5, p. 717-724Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study
Kater, A. P., Spiering, M., Liu, R. D., Doreen te Raa, G., Slinger, E., Tonino, S. H., Beckers, M. M., Daenen, S., Doorduijn, J. K., Lankheet, N. A. G., Luijks, D. M., Eldering, E. & van Oers, M. H. J., 2014, In: Leukemia research. 38, 1, p. 34-41How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater, A. P., Tonino, S. H., Egle, A. & Ramsay, A. G., 2014, In: Blood. 124, 14, p. 2184-2189miR in CLL: more than mere markers of prognosis?
Kater, A. P. & Eldering, E., 2014, In: Blood. 124, 1, p. 2-4The half-life of guidelines for Waldenström's macroglobulinaemia; short stickiness for a sticky disease?
Kater, A. P., Mar 2013, In: Netherlands journal of medicine. 71, 2, p. 52-3 2 p.A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
Hoogeboom, R., van Kessel, K. P. M., Hochstenbach, F., Wormhoudt, T. A., Reinten, R. J. A., Wagner, K., Kater, A. P., Guikema, J. E. J., Bende, R. J. & van Noesel, C. J. M., 2013, In: Journal of experimental medicine. 210, 1, p. 59-70Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model
Lascano, V., Guadagnoli, M., Schot, J. G., Luijks, D. M., Guikema, J. E. J., Cameron, K., Hahne, M., Pals, S., Slinger, E., Kipps, T. J., van Oers, M. H. J., Eldering, E., Medema, J. P. & Kater, A. P., 2013, In: Blood. 122, 24, p. 3960-3963Chronische lymfatische leukemie in Nederland: Trends in incidentie, behandeling en overleving (1989-2008)
van den Broek, E. C., Kater, A. P., van de Schans, S. A., Karim-Kos, H. E., Janssen-Heijnen, M. L., Peters, W. G., Nooijen, P. T., Coebergh, J. W. & Posthuma, E. F., 2013, In: Nederlands tijdschrift voor hematologie. 10, p. 244-253Highlights of the 7th young investigators' meeting on chronic lymphocytic leukemia
Lanasa, M. C., Kater, A. P., Shanafelt, T. & Fischer, K., 2013, In: Leukemia & lymphoma. 54, 8, p. 1815-1816IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells
Pascutti, M. F., Jak, M., Tromp, J. M., Derks, I. A. M., Remmerswaal, E. B. M., Thijssen, R., van Attekum, M. H. A., van Bochove, G. G., Luijks, D. M., Pals, S. T., van Lier, R. A. W., Kater, A. P., van Oers, M. H. J. & Eldering, E., 2013, In: Blood. 122, 17, p. 3010-3019Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia
te Raa, G. D., Malcikova, J., Pospisilova, S., Trbusek, M., Mraz, M., Garff-Tavernier, M. L., Merle-Béral, H., Lin, K., Pettitt, A. R., Merkel, O., Stankovic, T., van Oers, M. H., Eldering, E., Stilgenbauer, S., Zenz, T. & Kater, A. P., 2013, In: Leukemia & lymphoma. 54, 8, p. 1849-1853Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia
Jethwa, A., Hüllein, J., Stolz, T., Blume, C., Sellner, L., Jauch, A., Sill, M., Kater, A. P., te Raa, G. D., Geisler, C., van Oers, M., Dietrich, S., Dreger, P., Ho, A. D., Paruzynski, A., Schmidt, M., von Kalle, C., Glimm, H. & Zenz, T., 2013, In: British journal of haematology. 163, 4, p. 496-500The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia
de Weerdt, I., Eldering, E., van Oers, M. H. & Kater, A. P., 2013, In: Leukemia research. 37, 7, p. 838-847The half-life of guidelines for Waldenstrom's macroglobulinaemia; short stickiness for a sticky disease?
Kater, A. P., 2013, In: Netherlands journal of medicine. 71, 2, p. 52-53 2 p.Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1
Oostvogels, R., Minnema, M. C., van Elk, M., Spaapen, R. M., te Raa, G. D., Giovannone, B., Buijs, A., van Baarle, D., Kater, A. P., Griffioen, M., Spierings, E., Lokhorst, H. M. & Mutis, T., 2013, In: Leukemia. 27, 3, p. 642-649Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989-2008
van den Broek, E. C., Kater, A. P., van de Schans, S. A. M., Karim-Kos, H. E., Janssen-Heijnen, M. L. G., Peters, W. G., Nooijen, P. T. G. A., Coebergh, J. W. W. & Posthuma, E. F. M., 2012, In: European journal of cancer (Oxford, England. 48, 6, p. 889-895Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis
te Raa, G. D., Tonino, S. H., Remmerswaal, E. B. M., van Houte, A. J., Koene, H. R., van Oers, M. H. & Kater, A. P., 2012, In: Leukemia & lymphoma. 53, 11, p. 2321-2325Donor-Derived Fat Tissue As a Source for Lipofilling After Allogeneic Hematopoietic Cell Transplantation
Lapid, O., van der Horst, C. M. & Kater, A. P., 2012, In: Journal of clinical oncology. 30, 17, p. E154-E155ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
Pospisilova, S., Gonzalez, D., Malcikova, J., Trbusek, M., Rossi, D., Kater, A. P., Cymbalista, F., Eichhorst, B., Hallek, M., Döhner, H., Hillmen, P., van Oers, M., Gribben, J., Ghia, P., Montserrat, E., Stilgenbauer, S. & Zenz, T., 2012, In: Leukemia. 26, 7, p. 1458-1461Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia
Tonino, S. H., van de Berg, P. J., Yong, S. L., ten Berge, I. J., Kersten, M. J., van Lier, R. A. W., van Oers, M. H. & Kater, A. P., 2012, In: Leukemia & lymphoma. 53, 9, p. 1785-1794Highlights of the 6th Young Investigators' Meeting on chronic lymphocytic leukemia
Kater, A. P., Shanafelt, T., Fischer, K. & Wierda, W., 2012, In: Leukemia & lymphoma. 53, 11, p. 2312-2313HOVON 109: de effectiviteit en veiligheid van eerstelijnsbehandeling van chronische lymfatische leukemie met chloorambucil, rituximab en lenalidomide bij oudere patienten en patienten met comorbiditeit; een fase I/II-studie
Kater, A. P., Chamuleau, M. E., Posthuma, W., Schipperus, M. R., Spiering, M. & van Oers, M. H., 2012, In: Nederlands tijdschrift voor hematologie. 9, p. 197Monoclonal B-cell lymphocytosis: Recommendations from the Dutch Working Group on CLL for daily practice
te Raa, G. D., van Oers, M. H. & Kater, A. P., 2012, In: Netherlands journal of medicine. 70, 5, p. 236-241Monoklonale B-cellymfocytose: incidentie, risicostratificatie en aanbevelingen voor de dagelijkse praktijk
te Raa, G. D., van Oers, M. H. & Kater, A. P., 2012, In: Nederlands tijdschrift voor hematologie. 9, p. 138Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
Tromp, J. M., Geest, C. R., Breij, E. C. W., Elias, J. A., van Laar, J., Luijks, D. M., Kater, A. P., Beaumont, T., van Oers, M. H. J. & Eldering, E., 2012, In: Clinical cancer research. 18, 2, p. 487-498CLL: Nu werken aan behandeling van de toekomst
Kater, A. P., 2011, In: Hematology news international. 5, 6, p. 21-23Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas
Guadagnoli, M., Kimberley, F., Phan, U., Cameron, K., Vink, P., Rodermond, H., Eldering, E., Kater, A., van Eenennaam, H. & Medema, J. P., 2011, In: Blood. 117, 25, p. 6856-6865DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing
Mohr, J., Helfrich, H., Fuge, M., Eldering, E., Bühler, A., Winkler, D., Volden, M., Kater, A. P., Mertens, D., te Raa, D., Döhner, H., Stilgenbauer, S. & Zenz, T., 2011, In: Blood. 117, 5, p. 1622-1632Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011
Kater, A. P., Wittebol, S., Chamuleau, M. E. D., van Gelder, M. & van Oers, M. H. J., 2011, In: Netherlands journal of medicine. 69, 10, p. 422-429Highlights of the 5th Young Investigators' Meeting on chronic lymphocytic leukemia
Fischer, K., Shanafelt, T. & Kater, A. P., 2011, In: Leukemia & lymphoma. 52, 7, p. 1391-1393Intracerebral Infiltration As the Unique Cause of the Clinical Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Tonino, S. H., Rijssenbeek, A. L., Oud, M. E., Pals, S. T., van Oers, M. H. & Kater, A. P., 2011, In: Journal of clinical oncology. 29, 34, p. E837-E839Richtlijnen diagnostiek en behandeling chronische lymfatische leukemie 2011
Kater, A. P., Wittebol, S., Chamuleau, M. E., van Gelder, M. & van Oers, M. H., 2011, In: Nederlands tijdschrift voor hematologie. 8, p. 190-201ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia
Tonino, S. H., van Laar, J., van Oers, M. H., Wang, J. Y., Eldering, E. & Kater, A. P., 2011, In: Oncogene. 30, 6, p. 701-713Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis
te Raa, G. D., Fischer, K., Verweij, W., van Houte, A. J., Kater, A. P. & Biesma, D. H., 2011, In: Clinical chemistry and laboratory medicine. 49, 1, p. 115-120Voor welke patiënten wordt ofatumumab vergoed?
Kater, A. P., 2011, In: HEMATOLOGIE ACTUEEL. 11, 5, p. onbekendWaxing and waning intravascular large cell lymphoma with widespread organ infiltration
Vos, J. M. I., Bordbar, A., Vet, R., Pals, S. T. & Kater, A. P., 2011, In: Leukemia & lymphoma. 52, 4, p. 705-708Chronic lymphocytic leukemia of Eμ-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression (Blood (2009) 114, 20 (4469-4476))
Enzler, T., Kater, A. P. & Zhang, W., 29 Jul 2010, In: Blood. 116, 4, p. 671 1 p.B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia
Zhang, W., Kater, A. P., Widhopf, G. F., Chuang, H-Y., Enzler, T., James, D. F., Poustovoitov, M., Tseng, P-H., Janz, S., Hoh, C., Herschman, H., Karin, M. & Kipps, T. J., 2010, In: Proceedings of the National Academy of Sciences of the United States of America. 107, 44, p. 18956-18960Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering
Tromp, J. M., Tonino, S. H., Elias, J. A., Jaspers, A., Luijks, D. M., Kater, A. P., van Lier, R. A. W., van Oers, M. H. J. & Eldering, E., 2010, In: Oncogene. 29, 36, p. 5071-5082R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia
Tonino, S. H., van Gelder, M., Eldering, E., van Oers, M. H. & Kater, A. P., 2010, In: Leukemia. 24, 3, p. 652-654Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study
Kater, A. P. & Tonino, S. H., 2010, In: Clinical lymphoma, myeloma & leukemia. 10, Suppl. 1, p. S34-S41Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression
Enzler, T., Kater, A. P., Zhang, W., Widhopf, G. F., Chuang, H-Y., Lee, J., Avery, E., Croce, C. M., Karin, M. & Kipps, T. J., 2009, In: Blood. 114, 20, p. 4469-4476Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction
Mous, R., Jaspers, A., Luijks, D. M. P., Mellink, C. H. M., van Oers, M. H. J., Kater, A. P. & Eldering, E., 2009, In: Leukemia. 23, 7, p. 1352-1355De tyrosinekinaseremmer dasatinib voor behandeling van chemotherapie-refractaire chronische lymfatische leukemie: de D'ACCORD-studie
Kater, A. P. & van Oers, M. H. J., 2009, In: Nederlands tijdschrift voor hematologie. 6, 8, p. 317-320miR-34a as part of the resistance network in chronic lymphocytic leukemia
Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Bühler, A., Kienle, D., Winkler, D., Dürig, J., van Oers, M. H. J., Mertens, D., Döhner, H. & Stilgenbauer, S., 2009, In: Blood. 113, 16, p. 3801-3808c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
Hallaert, D. Y. H., Jaspers, A., van Noesel, C. J., van Oers, M. H. J., Kater, A. P. & Eldering, E., 2008, In: Blood. 112, 13, p. 5141-5149De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie
Kater, A. P. & van Oers, M. H. J., 2008, In: Nederlands tijdschrift voor hematologie. 5, 6, p. 236-244Ernstige anemie door infectie met het Humaan parvovirus B19 bij een patiënt met een auto-immuun-hemolytische anemie en een B-cel-non-hodgkinlymfoom
van Dam, I. E., Kater, A. P., Hart, W. & van den Born, B. J. H., 2008, In: Nederlands tijdschrift voor geneeskunde. 152, 3, p. 153-157 5 p.Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature
Choi, G., van den Borne, M. P. J., Visser, C. E., Kersten, M. J. & Kater, A. P., 2008, In: Annals of hematology. 87, 9, p. 771-772In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow
van Gent, R., Kater, A. P., Otto, S. A., Jaspers, A., Borghans, J. A. M., Vrisekoop, N., Ackermans, M. A. T., Ruiter, A. F. C., Wittebol, S., Eldering, E., van Oers, M. H. J., Tesselaar, K., Kersten, M. J. & Miedema, F., 2008, In: Cancer research. 68, 24, p. 10137-10144No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia
Tonino, S. H., Spijker, R., Luijks, D. M. P., van Oers, M. H. J. & Kater, A. P., 2008, In: Blood. 112, 3, p. 840-843Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients
Sonke, G. S., Ludwig, I., van Oosten, H., Baars, J. W., Meijer, E., Kater, A. P. & de Jong, D., 2008, In: Clinical infectious diseases. 47, 1, p. 105-108Cellular immune therapy for chronic lymphocytic leukemia
Kater, A. P., van Oers, M. H. J. & Kipps, T. J., 2007, In: Blood. 110, 8, p. 2811-2818Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity
Smit, L. A., Hallaert, D. Y. H., Spijker, R., de Goeij, B., Jaspers, A., Kater, A. P., van Oers, M. H. J., van Noesel, C. J. M. & Eldering, E., 2007, In: Blood. 109, 4, p. 1660-1668The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4
Kater, A., Henke, M. O. & Rubin, B. K., 2007, In: Annals of the New York Academy of Sciences. 1112, p. 140-153Upper-airway obstruction instigated by Sweet's syndrome
Bouw, J., Kater, A. P., van Tongeren, J. & Schultz, M. J., 2007, In: Medical science monitor. 13, 4, p. CS53-CS55CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53
Dicker, F., Kater, A. P., Prada, C. E., Fukuda, T., Castro, J. E., Sun, G., Wang, J. Y. & Kipps, T. J., 2006, In: Blood. 108, 10, p. 3450-3457Novel apoptosis inducting strategies in chronic lymphocytic leukemia
Kater, A. P., 2006, 208 p.Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro
Rubin, B. K., Kater, A. P. & Goldstein, A. L., 2006, In: Chest. 130, 5, p. 1433-1440Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation
Mackus, W. J. M., Kater, A. P., Grummels, A., Evers, L. M., Hooijbrink, B., Kramer, M. H. H., Castro, J. E., Kipps, T. J., van Lier, R. A. W., van Oers, M. H. J. & Eldering, E., 2005, In: Leukemia. 19, 3, p. 427-434Chronic lymphocytic leukemia: time for a risk-adapted approach
Kater, A. P. & van Oers, M. H. J., 2005, Trends in leukemia research. Romero, R. M. (ed.). S.l.: Nova Science Publishers, Inc, p. 363-383Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells
Dicker, F., Kater, A. P., Fukuda, T. & Kipps, T. J., 2005, In: Blood. 105, 8, p. 3193-3198Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis
Kater, A. P., Dicker, F., Mangiola, M., Welsh, K., Houghten, R., Ostresh, J., Nefzi, A., Reed, J. C., Pinilla, C. & Kipps, T. J., 2005, In: Blood. 106, 5, p. 1742-1748Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia
Kater, A. P., Remmerswaal, E. B. M., Nolte, M. A., Eldering, E., van Oers, M. H. J. & van Lier, R. A. W., 2004, In: British journal of haematology. 126, 4, p. 512-516CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack
Kater, A. P., Evers, L. M., Remmerswaal, E. B. M., Jaspers, A., Oosterwijk, M. F., van Lier, R. A. W., van Oers, M. H. J. & Eldering, E., 2004, In: British journal of haematology. 127, 4, p. 404-415Chronische lymfatische leukemie: hoog tijd voor een op het risico afgestemd beleid
Kater, A. P. & van Oers, M. H. J., 18 Jan 2003, In: Nederlands tijdschrift voor geneeskunde. 147, 3, p. 104-9 6 p.Chronische lymfatische leukemie: Hoog tijd voor een op het risico afgestemd beleid
Kater, A. P. & van Oers, M. H. J., 2003, In: Nederlands tijdschrift voor geneeskunde. 147, 3, p. 104-110 7 p.Trombotische microangiopathie: trombocytopenie en hemolytische anemie
Kater, A. P., van der Lelie, J. & Levi, M., 7 Dec 2002, In: Nederlands tijdschrift voor geneeskunde. 146, 49, p. 2343-7 5 p.Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction
Kater, A. P., Peppelenbosch, M. P., Brandjes, D. P. M. & Lumbantobing, M., 2002, In: Clinical and diagnostic laboratory immunology. 9, 6, p. 1396-1397Immunogentherapie. Bestrijding leukemie door activatie afweersysteem met behulp van CD70
Kater, A. P. & van Oers, M. H. J., 2002, (E-pub ahead of print) In: Analyse (Amsterdam). oktober, p. 240-242Trombotische microangiopathie: Trombocytopenie en hemolytische anemie
Kater, A. P., van der Lelie, J. & Levi, M. M. M. ., 2002, In: Nederlands tijdschrift voor geneeskunde. 146, 49, p. 2343-2347 5 p.Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study
Schnog, J. B., Kater, A. P., Mac Gillavry, M. R., Duits, A. J., Lard, L. R., van der Dijs, F. P., Brandjes, D. P., ten Cate, H., van Eps, L. W. & Rojer, R. A., 2001, In: American journal of hematology. 68, 3, p. 179-183Toxin-mediated haemolytic uraemic syndrome without diarrhoea
Kater, A. P., Westermann, A. M., de Groot, M. R., von dem Borne, A. E. & Kuijper, E. J., 2000, In: Journal of internal medicine. 248, 3, p. 263-265Kwaliteit van leven bij kinderen met sikkelcelziekte in de regio Amsterdam
Kater, A. P., Heijboer, H., Peters, M., Vogels, T., Prins, M. H. & Heymans, H. S., 1999, In: Nederlands tijdschrift voor geneeskunde. 143, 41, p. 2049-2053Transient thrombocytopenia after cardiac surgery in infants with Down syndrome
Kater, A. P., Prins, M. H., von Rosenstiel, I. A., Ottenkamp, J. & Peters, M., 1999, In: Journal of pediatric hematology/oncology. 21, 2, p. 170-171Awards
AMC (Vrijgesteld)
Kater, A.
AMC (Vrijgesteld) Funding
Bureau Stichting Cancer Center Amsterdam
Kater, A.
Bureau Stichting Cancer Center Amsterdam
Europese Unie
Kater, A.
Europese Unie
Amsterdam UMC Foundation
Kater, A.
Amsterdam UMC Foundation
NWO
Kater, A. & de Haan, G.
NWO
Medical Research BV
Kater, A.
Medical Research BV
Abbvie Inc.
Kater, A.
Abbvie Inc.
AMC (Vrijgesteld)
Kater, A. & Heijmans, J.
AMC (Vrijgesteld) Funding
KWF Kankerbestrijding
Kater, A.
KWF Kankerbestrijding
AMC
Kater, A.
AMC Funding
LAVA Therapeutics
Kater, A.
LAVA Therapeutics
ZonMw
Kater, A. & Heijmans, J.
ZonMw
Owlstone Medical Ltd
Kater, A. & de Heer, K.
Owlstone Medical Ltd
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Amsterdam UMC Foundation
Kater, A.
Amsterdam UMC Foundation
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Amsterdam UMC, Locatie VU Medisch Centrum
Kater, A.
Amsterdam UMC - Vrije Universiteit Amsterdam
Genmab A/S
Kater, A.
Genmab A/S
VUmc Research B.V.
Kater, A.
VUmc Research B.V.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Juno Therapeutics Inc
Kater, A.
Juno Therapeutics Inc
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Europese Unie
Kater, A.
Europese Unie
AMC
Kater, A.
AMC Funding
Acerta Pharma B.V.
Kater, A.
Acerta Pharma B.V.
Syneos Health UK Limited
Kater, A.
Syneos Health UK Limited
Janssen Cilag B.V.
Kater, A.
Janssen Cilag B.V.
Stichting Hematologisch Oncologische Wetenschap
Kater, A.
Stichting Hematologisch Oncologische Wetenschap
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
KWF Kankerbestrijding
Kater, A.
KWF Kankerbestrijding
Stichting Hovon, p/a Erasmus MC, Ee-2155
Kater, A.
Stichting Hovon, p/a Erasmus MC, Ee-2155
Celgene International Il S?rl
Kater, A.
Celgene International Il S?rl
Acerta Pharmaceuticals
Kater, A.
Acerta Pharmaceuticals
IQVIA RDS Netherlands B.V.
Kater, A.
IQVIA RDS Netherlands B.V.
Projects
efficacy of plasma derived neutralizing antibodies in immunocompromized patients with COVID-19
Heijmans, J., Rijnders, B. & Kater, A.
Eldering E.: Apoptosis regulation in immuno-hematology
Eldering, E., Kater, A., Slinger, E., Tonino, S., Wensveen, F., van der Windt, G., Derks, I., Terpstra, S., van Attekum, M., Brocco, F., Delgado, R., Hofland, T. & Leeksma, A.
01/01/2007 → …
Kater A.P.: development of, circumvention of and novel strategies for (development of) chemorefractory CLL
van Attekum, M., Brocco, F., van Bruggen, A., Hofland, T., Leeksma, A., de Weerdt, I., Kater, A., Slinger, E., Tonino, S. & Wensveen, F.
01/06/2012 → …
van Oers M.H.J.: Pathogenesis and Immunotherapy of B cell malignancies
Gerritsen, M., Gillissen, M., Kroeze, A., Schimmel, M., Sins, J. W. R., van Tuijn, C., Biemond, B., Kater, A., Kersten, M. J., Zeerleder, S., Hazenberg, M., Slinger, E. & Tonino, S.
01/01/2006 → …
ID: 64520